The product is applied in addressing symptomatic relief across acute, moderate pain episodes, which may create noticeable interference with daily comfort. It is commonly used when pain symptoms are not adequately addressed by common single-ingredient pain relievers like paracetamol or ibuprofen alone. Its indications are for the short-term treatment of acute, moderate pain which is not relieved by paracetamol, ibuprofen or aspirin alone.

Therapeutic Applications

The medicine is relevant for easing symptoms that may interfere with daily comfort, and is commonly used to help with conditions such as headache, episodic migraine, backache, period pain, dental pain, and pain from sprains and strains. It is used in settings where short-term symptomatic assistance is needed, such as during phases of increased distress or discomfort.

“It is used in situations involving certain distressing symptoms, where supportive relief may help to ease distress and contribute to maintaining general well-being during symptomatic phases.”

This approach contributes to improved comfort during periods of heightened symptoms, and may help patients cope more steadily with symptom fluctuations.

---

QuickFact Block

Property	Description
Primary Target	Moderate pain not relieved by single analgesics
Typical Context	Acute, short-term, or episodic discomfort
Core Benefit	Provides supportive relief and helps ease symptom burden

Regulatory References

1. short-term treatment of acute, moderate pain which is not relieved by paracetamol, ibuprofen or aspirin alone

The eligibility for using Solpadeine Plus is strictly defined by regulatory authorities due to the presence of codeine, an opioid analgesic.

Eligibility Scope

Category	Official Regulatory Status
Populations Allowed	Adults and adolescents older than 12 years of age.
Populations Contraindicated	Children below the age of 12 years; women who are breastfeeding.

---

Eligibility Restrictions

Use of this medicine is absolutely contraindicated in several specific populations, primarily due to the risk of opioid toxicity from the variable metabolism of codeine to morphine:

• Pediatric Post-Surgery: Contraindicated for all children and adolescents (0–18 years) who undergo tonsillectomy and/or adenoidectomy for Obstructive Sleep Apnoea Syndrome.
• Metabolic Status: Contraindicated for individuals known to be CYP2D6 ultra-rapid metabolizers.
• Existing Conditions: Contraindicated in patients with severe respiratory depression, acute asthma, chronic constipation, or known hypersensitivity to any of the active ingredients.

Conditional Use

The product label advises caution and medical consultation for patients with renal or hepatic impairment, chronic alcoholism, or chronic malnutrition. Use during pregnancy is generally not recommended and requires medical assessment to ensure the benefit outweighs the potential risk.

Interactions with other medicines and products

This section outlines documented interactions based on official regulatory information for Solpadeine Plus (Paracetamol, Codeine, and Caffeine).

Contraindicated Combinations and Substances

Co-administration with other Paracetamol-containing products or Codeine-containing products is strictly restricted to prevent accidental overdose and toxicity. The product must not be taken concurrently with, or within two weeks of stopping, Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe reactions. Use in individuals known to be CYP2D6 ultra-rapid metabolizers is contraindicated due to increased risk of opioid toxicity.

Clinically Significant Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance Category	Interaction Effect	Constraints
CNS Depressants (e.g., Sedatives, Alcohol, Benzodiazepines)	Additive depressant effect with Codeine, increasing risk of sedation and respiratory depression.	Concurrent use requires caution/avoidance.
Anticoagulants (e.g., Warfarin)	Prolonged, regular use of Paracetamol may enhance the anticoagulant effect.	Increased monitoring for bleeding risk.
Absorption Modifiers (e.g., Metoclopramide, Domperidone, Colestyramine)	Some agents increase (Metoclopramide) or decrease (Colestyramine) the speed of Paracetamol absorption.	Colestyramine should not be administered within one hour of taking this product.
Enzyme Inducers (e.g., Phenytoin, Rifampicin)	May increase the formation of a potentially hepatotoxic metabolite of Paracetamol.	Use with caution.

Avoid excessive intake of other sources of caffeine (e.g., coffee, tea) due to the risk of nervousness and tachycardia. Consumption of alcohol is strongly advised against due to the risk of additive CNS depression and severe hepatotoxicity.

The mechanism of this combination product relies on three core actions. The Codeine component is converted into its active metabolite, which functions as an agonist at the mu-opioid receptor (mu-OR) in the central nervous system (CNS). This action hyperpolarizes specific nerve cells in the spinal cord and brainstem, disrupting the signaling sequence of the nociceptive pathway, resulting in the systemic elevation of the nociceptive threshold.

Acetaminophen acts by inhibiting the activity of the Cyclooxygenase (COX) enzyme system primarily within the CNS, reducing the production of Prostaglandin E2 ( PGE2). This modulates centralized nociceptive signaling and directly causes the antipyretic physiological effect by lowering the hypothalamic set point. The Caffeine component functions as a non-selective antagonist at Adenosine Receptors in the CNS, increasing neuronal activity. This action modulates the central activity of Acetaminophen, contributing to a combined mechanistic synergy. The Codeine mechanism is constrained by its need for metabolic conversion via the CYP2D6 enzyme and exhibits a ceiling effect due to receptor saturation.

How to Use Solpadeine Plus

As a combination analgesic, the use of Solpadeine Plus is defined by the dose of its active ingredients: Acetaminophen (Paracetamol) 500 mg, Codeine Phosphate 8 mg, and Caffeine 30 mg per tablet.

Administration and Dosing

Solpadeine Plus is for oral administration. The dosing regimen is dependent on age, and all use is intended to be short-term only.

Population	Dose per Administration	Minimum Interval	Max per 24 Hours
Adults (18+)	2 tablets	4 hours	8 tablets
Adolescents (12-18)	1-2 tablets	6 hours	8 tablets (16+) or 4 tablets (12-15)

Specific Use Conditions

Frequency and Duration: Adult doses may be repeated up to four times daily, provided the minimum 4-hour interval is observed. The product is for short-term treatment only, strictly limited to a maximum of 3 consecutive days.

Preparation: Soluble (effervescent) tablets must be fully dissolved in a glass of water before ingestion. Standard tablets should be swallowed whole with water.

Dosing Limits: It is essential that the stated maximum daily dose is not exceeded. For patients with renal impairment, the minimum interval between doses should be extended to at least 6 hours.

Recent Clinical Evidence

Efficacy in Acute Pain

Clinical trials and systematic reviews examining the combination of paracetamol (acetaminophen) and codeine—the primary active components of Solpadeine Plus—have focused largely on the management of acute moderate pain.

Evidence from single-dose, placebo-controlled studies, often in the context of postoperative pain, suggests that the addition of codeine to paracetamol provides additional analgesic benefit compared to paracetamol alone.

• One meta-analysis examining doses higher than those commonly found in over-the-counter preparations (e.g., paracetamol 600/650 mg plus codeine 60 mg) found that a clinically relevant proportion of participants achieved at least 50% pain relief in a single dose, significantly outperforming placebo.
• Comparisons of the combination product with paracetamol alone in acute pain models indicate that the addition of codeine increases the proportion of individuals who experience effective pain relief. The combination may also extend the duration of pain relief compared to paracetamol alone.

---

Safety and Tolerability Profile

Clinical safety data consistently note differences in the incidence of adverse effects between single-dose and multi-dose regimens:

Regimen	Adverse Event Profile vs. Paracetamol Alone
Single Dose	Incidence of side effects was generally reported as similar to paracetamol alone.
Multi-Dose	A significantly higher proportion of patients reported side effects, most frequently nausea, constipation, dizziness, and drowsiness.

The risk of developing dependence or tolerance is a recognized risk associated with the codeine component, particularly with repeated or prolonged use beyond the recommended short-term duration (typically limited to three consecutive days).

Key Studies & References

1. Label: ACETAMINOPHEN AND CODEINE tablet (FDA/DailyMed)
2. Investigating the efficacy and safety of over-the-counter codeine containing combination analgesics for pain and codeine based antitussives (TGA Review)
3. Managing Codeine Dependence (Therapeutic Goods Administration - TGA)

Common questions about Solpadeine Plus (FAQ)

Q: Can Solpadeine Plus be used for persistent pain that is not severe?

Official product information states this medicine is intended only for the short-term treatment of acute moderate pain. Due to the risk of codeine-related dependence, regulatory guidelines strictly limit use to a maximum of three consecutive days. It is not intended for the management of long-term or persistent pain.

Q: Are there common over-the-counter cold and flu products that can interact with this medicine?

Yes, regulatory guidelines strictly restrict taking any other medication that contains paracetamol or codeine. Many common over-the-counter cold and flu remedies include paracetamol, and taking them together with Solpadeine Plus raises the risk of a dangerous overdose.

Q: Is Solpadeine Plus appropriate for older adults or seniors?

Official regulatory information advises caution when this medicine is used by older adults. This is because seniors are generally more sensitive to the opioid component, codeine, which can increase the risk of side effects like dizziness and constipation. Consultation with a healthcare professional is advised for use in this population.

Q: What does 'opioid-related side effects' refer to in the context of Solpadeine Plus?

The opioid-related side effects come from the codeine component of the medicine. Regulatory documents state that these commonly affect the nervous system and gastrointestinal tract. Such effects may include drowsiness, dizziness, constipation, nausea, and confusion.

Q: Is Solpadeine Plus the same as Tylenol with Codeine?

No, they are not the same. While both products contain paracetamol (acetaminophen) and codeine, Solpadeine Plus contains an additional active ingredient, caffeine. This third ingredient is usually not found in standard Tylenol with Codeine preparations and contributes to the combined effect of the medicine.

Q: Can I take Solpadeine Plus if I am already taking an antidepressant?

Professional guidance should be sought before combining this medicine with an antidepressant. Regulatory warnings indicate that codeine can increase the effects of Central Nervous System (CNS) depressants, which includes certain types of antidepressants. Taking them together raises the risk of profound sedation or respiratory depression.

Q: How quickly can I generally expect Solpadeine Plus to start relieving pain?

The official product information states that the caffeine component is included to help speed up the absorption of the paracetamol. Paracetamol itself is rapidly absorbed, typically reaching its highest concentration in the body within 30 to 60 minutes.

Q: How long does the pain relief from Solpadeine Plus usually last?

The duration of the analgesic effect can be inferred from the regulatory dosing instructions. These instructions require a minimum interval of four hours between doses for adults, indicating the time period before the next dose may be taken.

Q: What food or herbal supplements are known to interact with the ingredients?

Official sources warn that the product may interact with certain herbal supplements, specifically St. John's Wort, as well as the amino acid Tryptophan. General food interactions are not listed, but avoidance of excessive caffeine from sources like coffee or tea is advised.

Q: Is it true that the Codeine component converts into Morphine in the body?

Yes, according to regulatory information, the analgesic effect of codeine is produced after it is converted in the liver into the active metabolite, morphine. This process requires a specific enzyme called CYP2D6 to function correctly.

Q: What is the official clinical evidence supporting the addition of caffeine to the formulation?

Official regulatory documents describe the combination of paracetamol and caffeine as a well-established analgesic combination. Caffeine is included to act as an adjuvant, which is a substance that enhances the pain-relieving effects of the paracetamol component.

Q: Are there any reported cases of Solpadeine Plus causing rebound headaches?

Official product labels include a general warning regarding medication-overuse headache. This is a recognized risk associated with the prolonged use of any painkiller for headache relief, which can paradoxically make headaches worse.

Q: Does taking this medicine affect your ability to drive a car or operate machinery?

Yes, regulatory documents state that this medicine can affect your ability to drive safely. Because it may cause side effects such as sleepiness or dizziness, patients are advised to refrain from driving or operating heavy machinery until they know how the medicine affects them.

Q: Are there patient groups that report not getting effective pain relief from Solpadeine Plus?

Yes, official safety information highlights the risk of reduced effectiveness in certain patient groups. Individuals identified as CYP2D6 poor metabolizers convert very little codeine into the active pain-relieving metabolite (morphine), which can result in insufficient or no analgesic effect.

Q: Is the Codeine component what makes it effective for migraine pain?

The product is officially indicated for the relief of symptoms associated with migraine. The presence of codeine makes the combination product suitable for moderate pain that is not relieved by non-opioid pain relievers alone.

Q: Is this medicine okay for someone who has a known caffeine sensitivity?

The product contains 30mg of caffeine per tablet, and this component can cause side effects like nervousness, irritability, or sleeplessness. Individuals with known sensitivity to caffeine are advised to discuss its use with a healthcare professional.

Q: What should I do if the drug does not seem to be working at all?

If the pain or fever persists for longer than the recommended maximum duration of three days or if the symptoms get worse, discontinuation of treatment is advised. Consultation with a healthcare professional is recommended immediately.

Q: Can I take this medication if I have a history of peptic ulcers?

Caution is generally advised for people with certain digestive tract issues. Patients with a history of inflammatory or obstructive bowel disorders or acute abdominal conditions are advised to seek consultation with a healthcare professional before use.

Storage and Disposal of Solpadeine Plus

The storage of Solpadeine Plus must adhere strictly to officially documented conditions to maintain product stability and ensure safety.

---

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 25 C (capsules) or below 30 C (soluble tablets). Do not freeze.
Protection	Keep in the original package, protected from moisture and light. Soluble tablets require the container to be kept tightly closed.
Expiry	Do not use the medicine after the expiry date (EXP) stated on the packaging.
Child Safety	Must be kept out of the sight and reach of children.

---

Disposal Instructions

Official regulatory guidance requires that unused or expired Solpadeine Plus must not be discarded via wastewater or thrown into ordinary household waste. To ensure proper pharmaceutical waste handling, the product should be returned to a pharmacist.